Merck and Moderna's mRNA Therapy Combo Shows Promising Results in Melanoma Trial
The Melanoma Research Foundation celebrated a landmark moment in melanoma treatment after Merck and Moderna announced positive Phase 3 results from the INTerpath-001 trial. The trial showed that an investigational, personalized mRNA-based therapy called intismeran autogene (V940), combined with KEYTRUDA, significantly improved recurrence-free survival and distant metastasis-free survival compared to KEYTRUDA alone in people with completely resected stage IIB-IV melanoma.
According to Professor Hussein Tawbi of The University of Texas MD Anderson Cancer Center, this breakthrough is a testament to the potential of personalized immunotherapy. He noted that checkpoint inhibitors have allowed researchers to uncover and amplify the immune impact of cancer therapies used for decades, and now, coupled with mRNA vaccine technology, we can finally unlock the potential for personalized treatment.
The therapy is designed using each patient's unique genetic 'fingerprint' to help train their immune system to recognize and fight cancer cells. The study will continue to evaluate overall survival, and the full data will be presented at an upcoming medical meeting and shared with regulators.